Blood test could guide lung cancer treatment in new trial
NCT ID NCT07661173
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 2 trial is testing a drug called firmonertinib for people with a specific type of advanced lung cancer (EGFR-mutated non-small cell lung cancer). The study uses a blood test (ctDNA) to decide if treatment should be adjusted over time. About 154 participants will receive firmonertinib alone or with chemotherapy and/or bevacizumab. The goal is to see if this personalized approach helps control the cancer longer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Firmonertinib (a targeted drug for EGFR-mutated lung cancer, sometimes combined with chemotherapy or bevacizumab)
What this could lead to
If successful, this could show that adjusting treatment based on ctDNA (a blood test) improves how long people live without their cancer getting worse.
What could go wrong
This is a small, early-phase trial (Phase 2) with only 154 people. It may not prove that ctDNA-guided therapy is better than standard care, and side effects from the drug combinations are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL-CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Anhui Provincial Cancer Hospital
Hefei, Anhui, China
Contact Phone: •••-•••-•••• Email: •••••@•••••